Post-earnings recap
Reported
Fri, Aug 6, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kymera Therapeutics reported a larger-than-expected loss per share, which contributed to a 4.43% decline in stock price following the announcement. The lack of revenue data and guidance may raise concerns among investors about the company's near-term outlook. Management's defensive tone suggests they are aware of the challenges ahead but are committed to their long-term strategy.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.55 | N/A | -157.01% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over current performance but remains focused on long-term goals. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to advance their pipeline despite the losses.